Mirae Ai Secures £2.9m in Early-Stage Funding to Advance Chronic Disease Management

Mirae Ai Limited, a London-based health technology company, has successfully raised an estimated £2.9m in an early-stage funding round. The company, which focuses on leveraging technology to support patients with chronic, complex, and severe medical conditions such as Crohn's and Ulcerative Colitis (IBD), formally allotted the new shares on April 1, 2026.

Founded recently on March 5, 2026, Mirae Ai aims to address the challenges faced by individuals managing long-term health conditions, asserting that "Living with IBD shouldn’t mean managing it alone." While the company's official registration encompasses "Other information technology service activities" and "Other human health activities," its stated mission clearly positions it within the burgeoning health tech sector, specifically targeting chronic disease management through technological solutions. As a newly established entity, Mirae Ai currently reports no employees and financial metrics such as revenue or profit/loss are not yet available.

The £2.9m funding round represents a significant initial capital injection for the nascent company. Details regarding the specific valuation at which this round was completed were not disclosed. Given the company's recent incorporation, this funding is indicative of a seed-stage investment, providing the foundational capital necessary to develop its platform and operations.

Key appointments around the time of the funding round include Joel Schoppig, who joined the board on April 1, 2026. LinkedIn suggests Mr. Schoppig may be linked to Health Tech Investment and Venture Building at Oxford Science Enterprises (OSE). Anuj Patel was also appointed as a director on March 5, 2026, with his LinkedIn profile indicating experience in change, transformation, and leadership within private equity contexts.

Further underscoring the strategic nature of this investment, Oxford Science Enterprises Plc was notified as a Person with Significant Control (PSC) on April 1, 2026. The corporate entity holds between 25 to 50 percent of Mirae Ai's shares and voting rights, signalling a substantial stake in the company. Oxford Science Enterprises, established in 2015, is a venture capital firm with a stated investment focus across life sciences, health technology, and deep technology sectors. The firm has a history of co-investing in health tech startups, including a $2 million co-investment in Neu Health, a London-based University of Oxford spinout focused on neurology care, in January 2025.

This funding round for Mirae Ai takes place within a dynamic, albeit mixed, UK health tech funding landscape. The sector has seen considerable activity, with UK health tech and life sciences startups raising $1.8 billion in venture capital investment in Q1 2025, making it the UK's most funded sector during that period. Nearly half of this investment in Q1 2025 was directed towards AI-powered startups, highlighting the growing influence of artificial intelligence in healthcare innovation.

However, more recent data for 2026 indicates a notable shift. HealthTech companies in the United Kingdom raised $177 million in equity funding across 34 rounds until April 2026. This represents a significant 80.64% drop in funding compared to the same period in 2025, when $915 million was raised across 43 rounds. Despite this, the UK remains a leading hub for digital health innovation in Europe, with the overall health tech market attracting over £2.8 billion in investment since 2020. While the broader biotech sector in the UK experienced a rebound in Q1 2026, with £516 million in VC investment, the specific health tech figures suggest a more cautious environment for early-stage companies.

Mirae Ai's successful £2.9m raise in this context demonstrates continued investor confidence in targeted health tech solutions, particularly those addressing chronic conditions. The involvement of Oxford Science Enterprises Plc as a significant shareholder further underscores the potential seen in Mirae Ai's approach to leveraging technology for patient well-being.